(secondQuint)Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years.

 Patients will received Imatinib at a dose of 400mg daily.

 Tolerability and quality of life will be assessed Secondary objectives are : to evaluate the survival without progression, the survival without event, the overall survival, the hematologic, cytogenetic and molecular responses at various check points.

 Duration of responses and failure to respond will be evaluated.

.

 Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years@highlight

The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis of cml is being performed within 1 year.

 Quality of life will be carefully assessed.

